Table IV.

ROC curves of potential volatile biomarkers.

Volatile metabolite	Cut-off value	Sensitivity	Specificity	AUC	P-value	AUC 95% CI
4-Heptanone
B-NHL vs. non-lymphoma	224.27	0.794	0.841	0.835	<0.001	0.763–0.907
B-NHL vs. BLD	198.02	0.809	0.758	0.775	<0.001	0.677–0.874
B-NHL vs. HC	144.87	0.868	0.867	0.901	<0.001	0.838–0.964
AB vs. IB	440.38	0.686	0.758	0.687	0.008	0.555–0.818
Early-stage vs. advanced	412.45	0.684	0.735	0.742	0.002	0.613–0.870
2-Methylpyrazine
B-NHL vs. non-lymphoma	38.79	0.824	0.619	0.714	<0.001	0.623–0.805
B-NHL vs. HC	21.78	0.971	0.800	0.885	<0.001	0.792–0.978
Low IPI vs. high IPI	66.05	0.696	0.818	0.765	<0.001	0.634–0.897
2-Methylbutanal
B-NHL vs. non-lymphoma	42.86	0.721	0.556	0.634	0.008	0.539–0.730
B-NHL vs. HC	42.86	0.721	0.833	0.777	<0.001	0.673–0.881
AB vs. IB	69.94	0.743	0.909	0.798	<0.001	0.678–0.919
CD20+ vs. CD20−	69.59	0.750	0.840	0.848	<0.001	0.746–0.950
2,6-Dimethyl-7-octen-2-ol
Early-stage vs. advanced	333.77	0.737	0.694	0.734	0.003	0.608–0.860
Decanoic acid
AB vs. IB	48.04	0.629	0.788	0.657	0.026	0.523–0.792
CD20+ vs. CD20−	40.70	0.780	0.910	0.851	<0.001	0.874–0.986
Combined ROC models
B-NHL vs. non-lymphoma	–	–	–	0.878	<0.001	0.819–0.937
B-NHL vs. HC	–	–	–	0.968	<0.001	0.938–0.997
AB vs. IB	–	–	–	0.824	<0.001	0.806–0.912
CD20+ vs. CD20−	–	–	–	0.908	<0.001	0.830–0.986
Early-stage vs. advanced	–	–	–	0.941	<0.001	0.890–0.992

AUC, area under the curve; B-NHL, B-cell non-Hodgkin's lymphoma; AB, aggressive B-NHL; IB, indolent B-NH; BLD, benign lymphatic diseases; CI, confidence interval; HC, healthy control; IPI, International Prognostic Index; ROC, receiver operating characteristic.